ID: ALA4100761

Max Phase: Preclinical

Molecular Formula: C24H28N6O11

Molecular Weight: 576.52

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)Cn2cc(-c3ccc(C(=O)O)cc3)nn2)OC(C(=O)O)=C[C@@H]1NC(=O)NCCC(=O)O

Standard InChI:  InChI=1S/C24H28N6O11/c1-11(31)26-19-14(27-24(40)25-7-6-18(33)34)8-17(23(38)39)41-21(19)20(35)16(32)10-30-9-15(28-29-30)12-2-4-13(5-3-12)22(36)37/h2-5,8-9,14,16,19-21,32,35H,6-7,10H2,1H3,(H,26,31)(H,33,34)(H,36,37)(H,38,39)(H2,25,27,40)/t14-,16+,19+,20+,21+/m0/s1

Standard InChI Key:  DGKKDPSWUSYZSR-GGPQYSQQSA-N

Associated Targets(Human)

Sialidase 2 382 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Sialidase 1 236 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Sialidase 3 398 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Sialidase 4 267 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 576.52Molecular Weight (Monoisotopic): 576.1816AlogP: -1.62#Rotatable Bonds: 12
Polar Surface Area: 262.53Molecular Species: ACIDHBA: 11HBD: 8
#RO5 Violations: 3HBA (Lipinski): 17HBD (Lipinski): 8#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.15CX Basic pKa: CX LogP: -2.14CX LogD: -11.92
Aromatic Rings: 2Heavy Atoms: 41QED Weighted: 0.14Np Likeness Score: -0.29

References

1. Guo T, Dätwyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW..  (2018)  Selective Inhibitors of Human Neuraminidase 3.,  61  (5): [PMID:29425031] [10.1021/acs.jmedchem.7b01574]
2.  (2018)  Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase,